CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 109 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2021. The put-call ratio across all filers is 0.33 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $35,776 | -31.3% | 1,638,858 | 0.0% | 1.53% | -5.0% |
Q2 2023 | $52,099 | +11.6% | 1,638,858 | -14.4% | 1.62% | -41.8% |
Q1 2023 | $46,694 | -22.1% | 1,914,466 | +0.8% | 2.78% | -17.0% |
Q4 2022 | $59,926 | -99.9% | 1,900,000 | -5.0% | 3.34% | +38.7% |
Q3 2022 | $56,520,000 | +42.5% | 2,000,000 | +33.3% | 2.41% | +13.9% |
Q2 2022 | $39,660,000 | -24.5% | 1,500,000 | 0.0% | 2.12% | -3.7% |
Q1 2022 | $52,515,000 | +8.0% | 1,500,000 | 0.0% | 2.20% | +66.6% |
Q4 2021 | $48,630,000 | -8.4% | 1,500,000 | -16.7% | 1.32% | +11.1% |
Q3 2021 | $53,100,000 | +3.6% | 1,800,000 | -10.0% | 1.19% | +14.2% |
Q2 2021 | $51,240,000 | +49.3% | 2,000,000 | -20.0% | 1.04% | +71.6% |
Q1 2021 | $34,325,000 | -9.3% | 2,500,000 | +9.5% | 0.61% | -25.4% |
Q4 2020 | $37,837,000 | – | 2,282,100 | – | 0.81% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,912,345 | 41.46% |
Perceptive Advisors | 6,511,727 | $205,379,869 | 5.77% |
Finepoint Capital LP | 517,287 | $16,315 | 5.28% |
Artal Group S.A. | 1,900,000 | $59,926 | 3.34% |
Affinity Asset Advisors, LLC | 215,000 | $6,781,100 | 2.66% |
Rock Springs Capital Management LP | 2,506,464 | $79,053,875 | 1.90% |
Hood River Capital Management LLC | 923,638 | $29,131,543 | 1.06% |
Logos Global Management LP | 260,000 | $8,200,400 | 0.96% |
Frazier Life Sciences Management, L.P. | 393,000 | $12,395,220 | 0.77% |
FEDERATED HERMES, INC. | 2,867,451 | $90,439,405 | 0.25% |